Compare PPBT & DCOY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PPBT | DCOY |
|---|---|---|
| Founded | 2010 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0M | 5.8M |
| IPO Year | N/A | N/A |
| Metric | PPBT | DCOY |
|---|---|---|
| Price | $0.58 | $0.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 98.6K | ★ 6.3M |
| Earning Date | 03-09-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $0.51 |
| 52 Week High | $3.48 | $35.70 |
| Indicator | PPBT | DCOY |
|---|---|---|
| Relative Strength Index (RSI) | 35.44 | 45.25 |
| Support Level | $0.56 | $0.72 |
| Resistance Level | $0.73 | $0.89 |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 23.33 | 1.61 |
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
Decoy Therapeutics Inc is a preclinical-stage biotechnology company developing peptide conjugate drug candidates using machine learning, artificial intelligence tools, and high-throughput synthesis techniques. The company's initial pipeline is focused on respiratory viruses and GI cancers.